US FDA Inspects Aurobindo's Subsidiary; Facility Receives 'Official Action Indicated' Classification
The United States Food and Drug Administration (US FDA) has concluded an inspection of Eugia Unit-III, a formulation manufacturing facility belonging to Eugia Pharma Specialities Ltd., a wholly owned subsidiary of Aurobindo Pharma Limited. The inspection process highlighted several observations regarding the manufacturing site in Telangana.The US FDA conducted the inspection at the Pashamylaram facility located at Phase-III, TSIIC, EPIP, IDA, Pashamylaram, Patancheru Revenue Mandal, Sangareddy District, 502307, Telangana. The inspection took place from January 27 to February 06, 2026.
Following the assessment by the FDA, the facility has been classified as 'official action indicated' (OAI).
A summary of the regulatory event is provided below:
| Particulars | Details |
|---|---|
| Authority | United States Food and Drug Administration (US FDA) |
| Inspection Facility | Eugia Unit-III, Formulation manufacturing facility of Eugia Pharma Specialities Ltd. |
| Inspection Dates | January 27 to February 06, 2026 |
| Observations/Action | The inspection concluded with 11 observations, and the classification is 'official action indicated' (OAI). |
Aurobindo Pharma Limited stated that there is no impact on the Company's financials or operations due to the outcome of this action.
The company affirmed its commitment to maintaining the highest quality manufacturing standards across all its global facilities and advised that stakeholders would be kept informed should any further information emerge relating to the matter.
AUROPHARMA Stock Price Movement
Today, Aurobindo Pharma Limited shares edged higher to close at ₹1472.8 after gaining 0.27%. The stock traded within a range of ₹1462.5 to ₹1481 during the session, with 669,347 shares recorded in volume.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.